Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Argatroban

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Suspended1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00861692Phase 2CompletedPrimary

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

NCT02501434Phase 2Suspended

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

Showing all 2 trials

Research Network

Common Treatments

  • Argatroban1
  • Heparin1

Active Sponsors

  • Tanabe Pharma Corporation1
  • Robert F. James1
  • Indiana University1

Top Investigators

Related Conditions

  • Aneurysmal Subarachnoid Hemorrhage1
  • Vasospasm Intracranial1
  • Intracranial Aneurysm1
  • Neurobehavioral Manifestations1

Activity Timeline